Wave Life's WVE‑006 shows restoration signals

Alpha-1 antitrypsin deficiency is an inherited disorder where the body makes too little protective AAT protein for the lungs and too much misfolded protein in the liver. Wave Life Sciences is trying to fix that at the RNA level with WVE-006. (clinicaltrials.gov) (wavelifesciences.com) RNA is the temporary instruction sheet cells read to make proteins. WVE-006 is designed to edit one letter in the SERPINA1 message so cells can make normal M-AAT instead of mutant Z-AAT. (wavelifesciences.com) (oligotherapeutics.org) Wave said on April 28 that new RestorAATion-2 data, including a 400 mg monthly cohort and a 600 mg single-dose cohort, will be presented during the American Thoracic Society meeting in May 2026. The company also said Food and Drug Administration feedback on a possible accelerated approval path is still expected in mid-2026. (wavelifesciences.com) (biospace.com) The reason investors are watching is the September 3, 2025 update from the same study. Wave said repeat 200 mg doses produced 11.9 µM total AAT and 7.2 µM corrected M-AAT, while a 400 mg single dose reached 12.8 µM total AAT and 5.3 µM M-AAT. (wavelifesciences.com) Wave also said one Pi*ZZ participant reached 20.6 µM total AAT and 10.3 µM M-AAT during an acute phase response, which the company described as the first restored physiological AAT production seen in that setting. The company said WVE-006 remained well tolerated in the cohorts reported at that time. (wavelifesciences.com) Today’s treatment backdrop is narrow. Licensed augmentation therapy is generally a weekly intravenous infusion for lung disease, and sources cited by patient and trial materials say no approved drug treats the liver form of alpha-1 antitrypsin deficiency. (clinicaltrials.gov) (alpha1.org) (lung.org) That is why Wave keeps emphasizing “dynamic” production. Instead of infusing replacement protein from outside the body, WVE-006 is meant to let the patient’s own liver make normal AAT when the body signals for more. (wavelifesciences.com) Wave regained full rights to WVE-006 from GSK in February and said the program is now fully under its control as it pushes toward regulatory discussions. The company reported $544.6 million in cash and cash equivalents as of March 31, 2026, with runway into the third quarter of 2028. (alpha1.org) (wavelifesciences.com) The next test is whether the May 2026 data extend the September signal in more patients and at higher dosing. For now, the company has shown interim evidence that RNA editing can restore measurable AAT production in people with alpha-1 antitrypsin deficiency. (wavelifesciences.com 1) (wavelifesciences.com 2)